Shares of Hims & Hers Health experienced a decline on April 21 after Amazon introduced a new competing weight loss program, impacting investor sentiment.

Shares of Hims & Hers Health Inc. surged following news that Robert F. Kennedy Jr. is seeking to ease regulations on peptides, a move that could benefit the telehealth company.

Several stocks, including Bumble, Hims & Hers Health, Blue Owl, and Netskope, are making significant moves in premarket trading, indicating potential volatility for the upcoming trading session.

Hims & Hers Health, Inc. has provided a summary of its earnings call for the fourth quarter of 2025.

Hims & Hers Health, Inc. (HIMS) has announced a 2026 revenue forecast that surpasses market estimates, indicating strong projected financial performance.

Hims & Hers Health is being assessed for its potential for sustained long-term growth in the market.

Cedar Grove Capital Management reportedly profited from its short position in Hims & Hers Health, indicating a successful bearish bet on the telehealth company.

A new partnership with Novo is fueling long-term optimism for Hims & Hers Health, Inc. (HIMS), suggesting positive future growth prospects for the company.

An asset manager has divested its holdings in Hims & Hers Health, indicating a significant change in investment strategy for the healthcare company's stock.

Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration  AP News

An analysis suggests that Hims & Hers Health's expansion into the GLP-1 business may not materialize quickly enough to mitigate associated risks.

These are the stocks posting the largest moves in early trading.

Hims & Hers Health announced its latest financial results, with GAAP EPS of $0.08, surpassing estimates by $0.03, and revenue of $617.82M, which was in-line with expectations.

This article provides a summary of significant corporate deals and transactions that occurred this week, featuring companies such as Visa, Hims & Hers Health, and Salesforce.

Deutsche Bank expressed near-term growth concerns for Hims & Hers Health, Inc. (HIMS) following the reversal of its GLP-1 launch.

Hims & Hers Health saw its stock jump following news of the FDA's review of compounded peptide therapies, indicating market reaction to potential regulatory developments in the wellness sector.

Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.

Several stocks, including Hims & Hers Health, oil stocks, and Live Nation Entertainment, are making significant moves in premarket trading, with Hims & Hers specifically upgraded to Buy from Hold by Needham.

Barclays has lowered its price target on Hims & Hers Health, Inc. (HIMS) to $25 while keeping an Overweight rating.

After a 70% decline over the past year, questions arise about whether Hims & Hers Health stock can bounce back.